Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies

September 30, 2016 Group News

Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies.

Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesù Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua.

Zutphen, The Netherlands – 30 September 2016

read more